Top of the morning to you. Another busy day is unfolding here on the Pharmalot campus, where we are mulling over our cluttered calendar and plotting our next moves. No doubt, you can relate. After all, this is only the middle of the week and there is so much to be done. This calls, as you may imagine, for a hot cup of stimulation. We are sticking with salted caramel mocha for now, by the way. Feel free to join us. Meanwhile, here are some tidbits. The world is a busy place, yes? Hope you make your way today. …
The world’s first Covid-19 human challenge study will begin in the U.K. within a month, following approval from the U.K.’s clinical trials ethics body, The Guardian writes. The trial will involve up to 90 carefully selected, healthy adult volunteers aged between 18 and 30 being exposed to Covid-19 in a safe and controlled environment. The initial trial aims to establish the smallest amount of virus needed to cause infection, probe the body’s immune response, and explore how the virus is passed on from person to person.
About the Author Reprints
May one observe that if the Gates / Novartis collaboration achieves its’ goal – “designed to be affordable and simple” – that will have the potential to cripple many $400K+ USD per patient business models?